Sonic Healthcare

Europe Medical Diagnostics Market Insights Report 2024-2028 with Competitive Analysis of Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover - ResearchAndMarkets.com

Retrieved on: 
Friday, March 8, 2024
Medical Devices, Health, Pandemic, Coagulation, POC, Sonic Healthcare, Growth, Immunoassay, Government, Urbanization, Clinical chemistry, Eurofins Scientific, Attention, COVID-19, Quest Diagnostics, Hematology, Medicine, Infection, Diagnosis, Labcorp, IVD, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$109.91 billion in 2028, growing at a CAGR of 5.69%, for the time period of 2024-2028.
  • The report provides a comprehensive analysis of the European Medical Diagnostics Market.
  • The company profiles of leading players (Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover) are also presented in detail.

Multi-Billion Opportunities in the US Clinical Laboratory Tests Market, More than $109 Billion Revenue by 2029 - Arizton

Retrieved on: 
Thursday, February 8, 2024
Insurance, Pharmacy, Laboratory, Health, Specialization, Growth, COVID-19, Diagnosis, Telehealth, Community, OPKO Health, Labcorp, Sonic Healthcare, Compound annual growth rate, Hospital, Endocrinology, Patient, Community health center, Antibody, Quest Diagnostics, Consumer, Toxicology, Pharmaceutical industry

Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.

Key Points: 
  • Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.
  • Therefore, the competitive landscape in the country for the clinical laboratory tests market is highly localized and challenging.
  • Overall, the U.S. clinical laboratory tests market witnessed dynamic shifts driven by advancements in specialty testing, the prominence of hospital-based laboratories, and the continued demand for clinical and immunochemistry tests.
  • Competitive landscape analysis: A thorough examination of the market's competitive landscape is presented, including detailed information about companies operating in the US clinical laboratory tests market.

Multi-Billion Opportunities in the US Clinical Laboratory Tests Market, More than $109 Billion Revenue by 2029 - Arizton

Retrieved on: 
Thursday, February 8, 2024
Insurance, Pharmacy, Laboratory, Health, Specialization, Growth, COVID-19, Diagnosis, Telehealth, Community, OPKO Health, Labcorp, Sonic Healthcare, Compound annual growth rate, Hospital, Endocrinology, Patient, Community health center, Antibody, Quest Diagnostics, Consumer, Toxicology, Pharmaceutical industry

Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.

Key Points: 
  • Most US clinical laboratory test companies offer routine or specialized clinical diagnostic testing services or both depending on their scientific expertise, technologies, innovations, and relevant regulations.
  • Therefore, the competitive landscape in the country for the clinical laboratory tests market is highly localized and challenging.
  • Overall, the U.S. clinical laboratory tests market witnessed dynamic shifts driven by advancements in specialty testing, the prominence of hospital-based laboratories, and the continued demand for clinical and immunochemistry tests.
  • Competitive landscape analysis: A thorough examination of the market's competitive landscape is presented, including detailed information about companies operating in the US clinical laboratory tests market.

Harrison.ai Welcomes Robyn Denholm As Board Director

Retrieved on: 
Wednesday, July 19, 2023
Operating partner, Pathology, Artificial intelligence in healthcare, Tesla, Inc., Sonic Healthcare, Knowledge, Growth, AI, Automation, Medical device

SYDNEY, July 19, 2023 /PRNewswire/ -- Global technology leader Robyn Denholm has been announced as the newest member of the Harrison.ai board, the clinician-led healthcare artificial intelligence (AI) company.

Key Points: 
  • SYDNEY, July 19, 2023 /PRNewswire/ -- Global technology leader Robyn Denholm has been announced as the newest member of the Harrison.ai board, the clinician-led healthcare artificial intelligence (AI) company.
  • Denholm, who currently serves as Operating Partner of Blackbird Ventures and Chair of the Board of Directors at Tesla Inc, took on the role effective 1 July.
  • "I'm incredibly excited to be joining the Harrison.ai Board, having been a strategic advisor to the organisation for some time now," said Denholm.
  • "I look forward to working with the Board to realise the Harrison.ai mission to scale global healthcare capacity using AI."

Harrison.ai Welcomes Robyn Denholm As Board Director

Retrieved on: 
Wednesday, July 19, 2023
Operating partner, Pathology, Artificial intelligence in healthcare, Tesla, Inc., Sonic Healthcare, Knowledge, Growth, AI, Automation, Medical device

SYDNEY, July 19, 2023 /PRNewswire/ -- Global technology leader Robyn Denholm has been announced as the newest member of the Harrison.ai board, the clinician-led healthcare artificial intelligence (AI) company.

Key Points: 
  • SYDNEY, July 19, 2023 /PRNewswire/ -- Global technology leader Robyn Denholm has been announced as the newest member of the Harrison.ai board, the clinician-led healthcare artificial intelligence (AI) company.
  • Denholm, who currently serves as Operating Partner of Blackbird Ventures and Chair of the Board of Directors at Tesla Inc, took on the role effective 1 July.
  • "I'm incredibly excited to be joining the Harrison.ai Board, having been a strategic advisor to the organisation for some time now," said Denholm.
  • "I look forward to working with the Board to realise the Harrison.ai mission to scale global healthcare capacity using AI."

Experienced Executive Search Consultant Mike Mosunic Named President of Slone Partners Cybersecurity

Retrieved on: 
Tuesday, July 11, 2023
Columbia University, Psychology, USC Marshall School of Business, Private equity, PE, Applied physiology, Health, Chief commercial officer, Venture capital, Pathology, MBA, Creativity, Organization, Le Moyne College, Sonic Healthcare, Artificial intelligence, VC, Physiology, Computer security, Management, Mosun Belo-Olusoga

SOUTH RIDING, Va., July 11, 2023 /PRNewswire-PRWeb/ -- Slone Partners, one of the nation's leading life sciences and healthcare executive search firms, is pleased to announce the appointment of Mike Mosunic as President of Slone Partners Cybersecurity, its subsidiary that delivers leaders for innovative Private Equity (PE)-backed and Venture Capital (VC) companies in the cybersecurity industry.

Key Points: 
  • SOUTH RIDING, Va., July 11, 2023 /PRNewswire-PRWeb/ -- Slone Partners , one of the nation's leading life sciences and healthcare executive search firms, is pleased to announce the appointment of Mike Mosunic as President of Slone Partners Cybersecurity , its subsidiary that delivers leaders for innovative Private Equity (PE)-backed and Venture Capital (VC) companies in the cybersecurity industry.
  • Mosunic is an experienced executive search consultant who has led high-profile searches for Slone Partners since joining the company for a second time in 2020.
  • "Mike Mosunic is a highly passionate, driven, and visionary executive who understands the very vibrant and complex cybersecurity industry," said Slone Partners CEO Leslie Loveless .
  • "I am greatly honored to assume the role as President of Slone Partners Cybersecurity," said Mosunic.

First Distribution Agreement Executed with Sonic Healthcare

Retrieved on: 
Wednesday, July 5, 2023
Research, Medical Devices, Infectious Diseases, Genetics, Other Health, Health, Pharmaceutical, General Health, Science, Partnership, Sonic Healthcare, Standby Equity Distribution Agreement, Pathology, ASX, Patient, Distribution, Sonic, MAP, Pharmaceutical industry

Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia (Distribution Agreement).

Key Points: 
  • Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia (Distribution Agreement).
  • The announcement of the MetaPanel™ Distribution Agreement marks the first commercial agreement between Microba and Sonic Healthcare following the announcement to the ASX of the $17.8m strategic investment by Sonic Healthcare into Microba on 29 November 2022.
  • The execution of this Distribution Agreement now completes the first of those commercial distribution arrangements, providing exclusive distribution rights to deliver the MetaPanel™ test Australia-wide through the Sonic Healthcare Australia Pathology network.
  • Sonic Healthcare is a leading provider of high-quality pathology services and will lead the commercialisation efforts to deliver the MetaPanel™ test nationally.

EQS-News: SYNLAB AG: SYNLAB agrees to sell Swiss business to Sonic Healthcare

Retrieved on: 
Tuesday, June 27, 2023
Heart, SHL, Synlab Group, FY, ADR, ASX, FSE, Medicine, Sale, EBITDA, Hospital, Patient, Laboratory, Sonic Healthcare, Hospital Insurance and Diagnostic Services Act, SA, CHF, Pharmaceutical industry

SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced the sale of SYNLAB SUISSE SA to Sonic Healthcare (ASX:SHL; ADR:SKHHY), having received the required approvals of antitrust authorities.

Key Points: 
  • SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced the sale of SYNLAB SUISSE SA to Sonic Healthcare (ASX:SHL; ADR:SKHHY), having received the required approvals of antitrust authorities.
  • “After a careful review of our activities in Switzerland and the developments in the diagnostics sector as a whole, SYNLAB Group decided to accept Sonic Healthcare’s offer for SYNLAB SUISSE SA and to sell all of our operations in Switzerland,” said Mathieu Floreani, CEO of the SYNLAB Group.
  • Mathieu Floreani: “Our highly skilled SYNLAB colleagues across our 26 locations are at the heart of the business we have built in Switzerland.
  • As diagnostics are highly important for healthcare systems around the world, SYNLAB will continue providing early detection, prevention, and personalised medicine for future-proof healthcare.

LBB Specialties Makes Strategic Changes to its C-Suite

Retrieved on: 
Tuesday, February 14, 2023
CFO, San Jose State University, CHRO, Santa Clara University, McMaster University, Senior Professional Baseball Association, Boehringer Ingelheim, Meehan, Chemical industry, Sonic Healthcare, Strategic planning, Hank, Human resources, Debro, Acquisition, Human, AZ Electronic Materials, Engineering, LBB, Business administration, Organization, Information technology, Manhattanville College, Marketing, Growth, Communication, Chemical engineering, Management, Chemistry, History, Science, New York University, Conn

NORWALK, Conn, Feb. 14, 2023 /PRNewswire/ -- In addition to the previously announced appointment of Hank DeWolf as President and Chief Executive Officer in 2022, LBB Specialties (LBBS) welcomed three new executives to its leadership team to usher in a new era of growth.

Key Points: 
  • Alidina joined LBB Specialties in March 2022 following the acquisition of Debro Inc., where he held positions across several functional areas including operations, regulatory, and finance, and eventually served as Debro's CFO.
  • Meehan joined the LBB Specialties leadership team in April 2021 as Vice President, Human Resources.
  • Prior to joining LBB Specialties, Meehan served as Director of Human Resources at Boehringer Ingelheim and CBL Path, Inc., a division of Sonic Healthcare.
  • "It is an exciting time to lead LBB Specialties, as ingredients and specialty chemicals grow increasingly important to our way of life," said Hank DeWolf.

LBB Specialties Makes Strategic Changes to its C-Suite

Retrieved on: 
Tuesday, February 14, 2023
CFO, San Jose State University, CHRO, Santa Clara University, McMaster University, Senior Professional Baseball Association, Boehringer Ingelheim, Meehan, Chemical industry, Sonic Healthcare, Strategic planning, Hank, Human resources, Debro, Acquisition, Human, AZ Electronic Materials, Engineering, LBB, Business administration, Organization, Information technology, Manhattanville College, Marketing, Growth, Communication, Chemical engineering, Management, Chemistry, History, Science, New York University, Conn

NORWALK, Conn, Feb. 14, 2023 /PRNewswire/ -- In addition to the previously announced appointment of Hank DeWolf as President and Chief Executive Officer in 2022, LBB Specialties (LBBS) welcomed three new executives to its leadership team to usher in a new era of growth.

Key Points: 
  • Alidina joined LBB Specialties in March 2022 following the acquisition of Debro Inc., where he held positions across several functional areas including operations, regulatory, and finance, and eventually served as Debro's CFO.
  • Meehan joined the LBB Specialties leadership team in April 2021 as Vice President, Human Resources.
  • Prior to joining LBB Specialties, Meehan served as Director of Human Resources at Boehringer Ingelheim and CBL Path, Inc., a division of Sonic Healthcare.
  • "It is an exciting time to lead LBB Specialties, as ingredients and specialty chemicals grow increasingly important to our way of life," said Hank DeWolf.